ZNF300 and lung cancer: The most dominantly enriched gene in PDOs from oxaliplatin-resistant tumors was ZNF300 (log2 fold change 21, FDR <0.001, Figure 4B), which has previously been associated with platinum resistance in lung cancer cells.45